MedTrace Logo

Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent

NCT02474225 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2015-06-17

No results posted yet for this study

Summary

The introduction of additional fluid into the vitreous cavity by intravitreal therapy would be expected to cause an immediate rise in the intraocular pressure. This transient, short-term intraocular pressure elevation (lasting up to 30 minutes) after intravitreal anti-vascular endothelial growth factor therapy has been well describe. The investigators aim to study the prevalence of the sustained intraocular pressure elevation associated with intravitreal injection of anti-vascular endothelial growth factor agents.

Conditions

  • Intraocular Pressure

Interventions

DRUG

Intravitreal injection (bevacizumab or ranibizumab)

The intravitreal anti-vascular endothelial growth factor agent of 0.1 ml of bevacizumab (2.5 mg/0.1 ml) or ranibizumab (1 mg/0.1 ml)

Sponsors & Collaborators

  • Prince of Songkla University

    lead OTHER

Principal Investigators

  • Asst.Prof.Weerawat Kiddee, MD · Prince of Songkla University

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02474225 on ClinicalTrials.gov